Overview

Targeting ATR in Soft-tissue Sarcomas

Status:
Not yet recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of berzosertib in association with gemcitabine

Phase:

Phase 2

Details

Lead Sponsor:

Institut Bergonié

Collaborator:

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Treatments:

Gemcitabine